Benzinga | Jan 24, 2022 03:28PM EST

JP Morgan Upgrades ResMed to Overweight, Raises Price Target to $270

JP Morgan analyst David Low upgrades ResMed (NYSE:RMD) from Neutral to Overweight and raises the price target from $260 to $270.